- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Aminocaproic acid - hemostatic agent, an inhibitor of fibrinolysis. It blocks the action of plasminogen activators, inhibits the action of plasmin, partially inhibits kinins. Aminocaproic acid also has some antiallergic activity and slightly increases the antitoxic function of the liver.
To stop bleeding during surgical interventions and various pathological conditions, accompanied by increased fibrinolytic activity of the blood and tissues (after operations on the lungs, prostate, pancreas and thyroid gland). Prevention of the development of secondary hyperfibrinogenemia with massive transfusions of canned blood.
1 ml contains aminocaproic acid 50 mg
No customer reviews for the moment.
Dosage and Administration
Aminocaproic acid solution is administered intravenously.
For adults, the drug is administered intravenously in the form of a 5% solution in an amount up to 100 ml drip at a rate of 50-60 drops per minute (for 15-30 minutes). During the first hour it is recommended to inject 4–5 g (80–100 ml) of the preparation, and then, if necessary, 1 g (20 ml) every hour for about 8 hours or until the bleeding stops. In the case of continuing or re-bleeding injection of a 5% solution of aminocaproic acid, repeat every 4 hours.
The introduction of aminocaproic acid solution can be combined with the infusion of glucose solution, hydrolysates and antishock solutions. In acute fibrinolysis, when the content of fibrinogen in the blood drops sharply, the administration of aminocaproic acid must be supplemented with a subsequent infusion of fibrinogen.
- noise in ears,
- nasal congestion;
- skin rash;
- decrease in blood pressure;
- orthostatic hypotension;
- acute renal failure;
- subendocardial hemorrhage.
- valvular heart disease;
It can be combined with the introduction of hydrolysates, glucose solutions (solutions of dextrose), antishock solutions. In acute fibrinolysis, the administration of aminocaproic acid with a fibrinogen content of 2-4 g (maximum - 8 g) must be supplemented with a subsequent infusion.
Antiaggregate reduction while taking direct and indirect anticoagulants.
No drugs should be added to the aminocaproic acid solution.
Pregnancy and Lactation
Contraindicated in pregnancy and lactation.
Upon appointment Aminocaproic acid it is necessary to control the fibrinolytic activity of the blood and the content of fibrinogen.
There are reports of inappropriate use in women for the prevention of elevated blood loss during childbirth due to the possibility of thromboembolic complications in the postpartum period.
Increased side effects (dizziness, nausea, diarrhea, catarrh of the upper respiratory tract) and severe inhibition of fibrinolysis.
In cases of overdose, plasminogen activators should be promptly administered (streptokinase, urokinase or anistreptase).
- Synthesis and characterization of poly(succinimide-co-6-aminocaproic acid) by acid-catalyzed polycondensation of L-aspartic acid and 6-aminocaproic acid
- Selective cyclization of 6-aminocaproic acid adsorbed on silica gel to ϵ-caprolactam: IR analysis of adsorbed state
- Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid
- Biodegradable polyetheresteramides synthesized from ϵ-caprolactone, 6-aminocaproic acid, and poly(ethylene glycol)
- Pathological fibrinolytic states and their treatment with epsilon aminocaproic acid (EACA)
- High performance liquid chromatographic assay of Amicar, ε-aminocaproic acid, in plasma and urine after pre-column derivatization with o-phthalaldehyde for fluorescence detection
- ChemInform Abstract: Synthesis and Conformation of Gly—Gly Dipeptides Constrained with Phenylalanine-Like Aminocaproic Acid Linkers.
- ChemInform Abstract: Synthesis of ε-Aminocaproic Acid Trimer Butyl Ester and Schiff Bases Derived Therefrom.
- Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage
- Acute promyelocytic leukaemia and acquired α-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients
- Biomedical research of novel biodegradable copoly(amino acid)s based on 6-aminocaproic acid and L-proline
- Fibrin adhesive implant in wound healing repair of dental sockets with topical application of epsilon aminocaproic acid: Histological analysis
- Formation of [b3 − 1 + cat]+ ions from metal-cationized tetrapeptides containing β-alanine, γ-aminobutyric acid or ε-aminocaproic acid residues
- Fluorescamine use in high-performance liquid chromatographic determination of aminocaproic acid in serum
- Aminocaproic acid (AMICAR) in advanced colorectal carcinoma
- The direct conversion of 6-aminocaproic acid vapor into polymer single crystals
- Vinyl polymers containing amido and carboxyl groups as side substituents, 2. Thermodynamic and fourier-transform infrared spectroscopic studies for the protonation of poly(N-acryloylglycine) and poly(N-acryloyl-6-aminocaproic acid)
- Synthesis of comb-like methacryl polymers containing condensates of 11-aminoundecanoic- and 6-aminocaproic acid in the side chains
- Rapid thin-layer chromatographic microassay of ϵ-aminocaproic acid in urine
- Haemostatic activity of ethamsylate and aminocaproic acid adsorbed poly(2-hydroxyethyl methacrylate) particles
- Bacterial degradation of 6-aminocaproic acid polyamides (nylon 6) of low molecular weight
- Rapid chromatographic technique for the determination of ε-aminocaproic acid in physiological fluids
- Improved purification of the membrane-bound hydrogenase–sulfur-reductase complex from thermophilic archaea using ϵ-aminocaproic acid-containing chromatography buffers
- A prospective, randomized, double-blinded single-site control study comparing blood loss prevention of tranexamic acid (TXA) to epsilon aminocaproic acid (EACA) for corrective spinal surgery